Trial intelligence / Profile preview

Perioperative vs Adjuvant Gemcitabine/Cisplatin in Node+ NSCLC

NCT00490659Phase 2Completed

Sponsor
Eli Lilly and Company
Start
Sep 2003
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Sep 2003; status: completed.

02

Drugs

gemcitabine
03

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on NCT00490659.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00490659.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call